Precigen

#Immuno-Oncology #Gene Therapy #Cell Therapy #Infectious Disease

Commercial-stage biopharmaceutical company developing gene and cell therapies for difficult-to-treat diseases, with a focus on immuno-oncology and precision medicine; its AdenoVerse immunotherapeutic platform received FDA platform technology designation in September 2026.

Company Info

Sector:Cell & Gene Therapy

Headquarters:Germantown, Maryland, USA

Founded:2018

Website:precigen.com/

Upcoming Milestones & Key Dates

2026

Regulatory

Expansion of AdenoVerse-based programs under FDA platform technology designation

Clinical Development Pipeline

PAPZIMEOS (zopapogene imadenovec)

Target: HPV E6/E7 (AdenoVerse)

Recurrent respiratory papillomatosis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PRGN-3005 UltraCAR-T

Target: MUC16

Advanced ovarian cancer

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

Clinical Regulatory•Sep 21, 2026•PR Newswire FDA

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform ↗

The FDA granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, which underpins its commercial product PAPZIMEOS, creating a pathway to leverage existing data and manufacturing for future AdenoVerse programs.

Leadership Team

Helen Sabzevari

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Careers

Various

Apply Now →